Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617-Reference-Cited by-同舟云学术

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

Published:2017-05-09 Issue:9 Volume:44 Page:1448-1454
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Ahmadzadehfar Hojjat,Wegen Simone,Yordanova Anna,Fimmers Rolf,Kürpig Stefan,Eppard Elisabeth,Wei Xiao,Schlenkhoff Carl,Hauser Stefan,Essler Markus

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s00259-017-3716-2/fulltext.html

Reference27 articles.

1. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The Theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015;56:1697–705. doi: 10.2967/jnumed.115.161299 .

2. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. doi: 10.1007/s00259-012-2298-2 .

3. Rai BP, Baum RP, Patel A, Hughes R, Alonzi R, Lane T, et al. The role of positron emission tomography with (68)gallium (Ga)-labeled prostate-specific membrane antigen (PSMA) in the Management of Patients with Organ-Confined and Locally Advanced Prostate Cancer Prior to radical treatment and after radical prostatectomy. Urology. 2016;95:11–5. doi: 10.1016/j.urology.2015.12.048 .

4. Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner F, et al. 68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016; doi: 10.2967/jnumed.116.178533 .

5. Braat A, Ahmadzadehfar H. Lutetium-177 labelled PSMA ligands for the treatment of metastatic castrate-resistant prostate cancer. Tijdschr Nucl Geneesk. 2016;38:1627–34.

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer;Cancers;2024-01-31

2. Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer;Annual Review of Medicine;2024-01-29

3. Precision Oncology with PSMA-Targeted α-Particle Therapy of mCRPC;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

4. Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [68Ga]Ga-RM2—A Head-to-Head Pilot Comparison with [68Ga]Ga-PSMA-11;Cancers;2023-12-29

5. Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review;Frontiers in Oncology;2023-11-16